Merck & Company (MRK) Buy, Sell or Hold

Home

Daily Stock Opinions and Ratings

Merck & Company (MRK)

152.55

+3.56 (2.39%)

as of Aug 21, 2026, 8:00:00 pm Market Open.

311 watching

Investor Insights

Aug 22, 2026, 12:00 am

This summary was created by AI, based on 25 opinions in the last 12 months.

Merck & Company (MRK) remains a focal point in the pharmaceutical sector, particularly due to its leading cancer treatment drug, Keytruda, which accounts for a significant portion of its revenue but faces a patent expiration in 2028. Experts note that while revenue growth has been modest in the past few years, recent breakthroughs in cancer trials have generated optimism for the company's potential future. There is a general recognition of Merck's strong pipeline of upcoming drugs, which could help offset the revenue decline anticipated from Keytruda going off-patent. Several experts have recommended strict stop-loss strategies to protect investments while pursuing gains, emphasizing a balance of growth potential and valuation concerns. Overall, the sentiment leans towards cautious optimism as analysts grapple with Merck's future amidst challenges and opportunities.

Consensus

positive

Valuation

fair value

Similar

Pfeizer, PFE

DON'T BUY

When the stock is not participating in a bull market, steer clear. A strong Company and well financed with good products but there is no real excitement. If the market rolls over, it would get hit hard.

BUY

Likes some of the major pharmaceuticals at these levels. Very cheap. Buy and hold.

STRONG BUY

A fantastic time to be buying this stock. If the pharmaceutical industry reverts to anything near normal, this is a huge screaming buy.

BUY

Missed its numbers. Demographics for drugs looks great. At a great price.

DON'T BUY

Not a fan. They don't have a very strong pipeline of promising drugs. Present drugs are facing competition from generics.

TOP PICK

Trading at a significant discount.Has been getting left behind.

PAST TOP PICK

(Was a top pick on May 21/03. Up 4.4%.) Still likes. Offers good value.

TOP PICK

2.5% dividend. Big name products. Only 14/15 X next years earnings. Recent studies suggest that some of their drugs may also be useful in preventing cancer.

TOP PICK

Trading at 16 X earnings, yielding 2.6%. Great pipeline of new drugs. Great balance sheet.

BUY

Good price. Good earnings price momentum.

TOP PICK

Health care sector is a good sector. 15/16 PE. Good price.

WEAK BUY

Some of their drugs have come off patent and they are having difficulty with Research /Development productivity. Prefers Pfizer.

TOP PICK

Pharmaceuticals look good in any upturn. 3% dividend. Trading at 15 X earnings. Had no earnings growth this year.

BUY

Demographics for pharmaceuticals is good. Could be volatile during their election period. Good long term.

BUY

Likes the valuations. Good balance sheet and good earnings.

Showing 271 to 285 of 310 entries

Most Recent Experts

Rob Sechan, Managing Partner, New Edge Capital

New Edge Capital

Jenny Harrington, CEO, Gilman Hill Asset Management

Gilman Hill Asset Management

Josh Brown, CEO, Ritholtz Wealth Management

Ritholtz Wealth Management

Amy Raskin, CIO, Chevy Chase Trust

Chevy Chase Trust

Darren Sissons

Campbell Lee & Ross

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Summer Sale

Merck & Company (MRK)